SCHEMBL1633022

SCHEMBL1633022

NS(=O)(=O)c1ccc(Nc2ncc3cccc(-c4ccc(N5CCNC(=O)C5)nc4)c3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 5/20 0.44
▸ JUN P05412 2/20 0.43
▸ MAPK8 P45983 2/20 0.43
▸ IKBKB O14920 3/20 0.42
▸ PIK3CD O00329 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ DCLK1 O15075 1/20 0.42
▸ PIK3C2G O75747 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ MAPK7 Q13164 1/20 0.42
▸ LRRK2 Q5S007 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ CHUK O15111 1/20 0.42
▸ MTOR P42345 1/20 0.41
▸ SMG1 Q96Q15 1/20 0.41
▸ CA1 P00915 4/20 0.41
▸ CA2 P00918 4/20 0.41
▸ CA9 Q16790 4/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ CA12 O43570 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633189 0.89 SMG1 (0.50) IKBKBPIK3CDAURKADCLK1PIK3C2G
SCHEMBL1632843 0.89 IKBKB (0.42) IKBKBPIK3CDAURKADCLK1PIK3C2G
SCHEMBL1632747 0.89 CA1 (0.41) IKBKBPIK3CDAURKADCLK1PIK3C2G
SCHEMBL1633314 0.86 MAPK10 (0.49) MAPK10JUNMAPK8IKBKBMTOR
SCHEMBL1632149 0.86 CA1 (0.42) IKBKBCHUKSMG1CA1CA2
SCHEMBL1633192 0.84 JAK2 (0.55) MAPK10JUNMAPK8IKBKBPIK3CD
SCHEMBL1633868 0.84 MAPK10 (0.57) MAPK10JUNMAPK8MTORSMG1
SCHEMBL12724257 0.83 MAPK10 (0.46) MAPK10JUNMAPK8IKBKBPIK3CD
SCHEMBL13498291 0.82 MAPK10 (0.46) MAPK10JUNMAPK8IKBKBPIK3CD
SCHEMBL1633943 0.81 MAPK10 (0.47) MAPK10JUNMAPK8IKBKBPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 MAPK10 402/4885JUN 544/4885MAPK8 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback